A prospective observational research report on the incidence of prostate cancer in western populations focused on a group of BRCA1/BRCA2 pathogenic variant carriers and a control group that underwent predictive testing and finally tested negative for a pathogenic germline BRCA1/BRCA2 variant [19]. The gene discussed is BRCA2; the disease is prostate carcinoma.